$110.14 -4.53 (-3.95%) Intercept Pharmaceuticals Inc - NASDAQ

Jan. 20, 2017 | 04:00 PM

Quotes

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Last Trade: 110.14
Trade Time: Jan 20 04:00 PM Eastern Daylight Time
Change: -4.53 (-3.95%)
Prev Close: 114.67
Open: 112.22
Bid: 110.05
Ask: 110.12
  1. Conatus Pharma Skyrockets On Novartis NASH Liver Drug Licensing Deal

    Investors Business Daily | Dec. 19, 2016 | 17:52PM EST
  2. Can-Fite An Emerging NASH Play With CF102

    TalkMarkets | Oct. 13, 2016 | 09:10AM EST
  3. 5 Biotech Stocks to Watch as Interest in NASH Increases

    TalkMarkets | Sep. 22, 2016 | 13:45PM EST
  4. Keep an Eye on These 7 Stocks for February 16, 2016

    Benzinga | Feb. 16, 2016 | 04:22AM EST
  5. Benzinga's Weekend M&A Chatter

    Benzinga | Feb. 15, 2016 | 19:35PM EST
  6. Intercept Pharma Spikes On Report That It’s Exploring A Sale

    IBD | Feb. 12, 2016 | 15:30PM EST
  7. Intercept Pharmaceuticals Soars 30%; Reuters Reported Company Exploring A Potential Sale

    Benzinga | Feb. 12, 2016 | 13:43PM EST
  8. Benzinga's Top Upgrades

    Benzinga | Jan. 29, 2016 | 09:14AM EST
  9. BioMarin, Intercept hit by FDA

    IBD | Dec. 18, 2015 | 18:47PM EST
  10. BioMarin, Intercept Pharma Drugs Face FDA Delays

    IBD | Dec. 18, 2015 | 12:13PM EST
  11. INTERCEPT PHARMA

    IBD | Dec. 17, 2015 | 19:25PM EST
  12. Intercept Pharma Higher On Takeover Rumor

    Benzinga | Dec. 15, 2015 | 14:08PM EST
  13. Intercept Presents New Data Analyses on Non-Invasive Liver Testing From FLINT Trial of Obeticholic Acid in Nonalcoholic Steatohepatitis at AASLD 2015

    Benzinga | Nov. 15, 2015 | 09:59AM EST
  14. Intercept Presents New Primary Biliary Cholangitis Data at AASLD 2015

    Benzinga | Nov. 15, 2015 | 09:57AM EST
  15. Benzinga's M&A Chatter for Tuesday November 10, 2015

    Benzinga | Nov. 10, 2015 | 20:19PM EST
Trading Center